These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Translating epigenetics into an anticancer drug pipeline for solid tumors. Roukos DH Expert Rev Med Devices; 2011 Jul; 8(4):409-13. PubMed ID: 21728725 [No Abstract] [Full Text] [Related]
3. Genetic discoveries propagate new epigenetic drugs. Garber K J Natl Cancer Inst; 2012 Feb; 104(3):174-6. PubMed ID: 22271768 [No Abstract] [Full Text] [Related]
4. Epigenetic cancer therapy makes headway. Mack GS J Natl Cancer Inst; 2006 Oct; 98(20):1443-4. PubMed ID: 17047192 [No Abstract] [Full Text] [Related]
5. What is the potential of epigenetics in drug development? Lundstrom K Future Med Chem; 2015; 7(3):239-42. PubMed ID: 25826357 [No Abstract] [Full Text] [Related]
6. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts. Nelson B Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980 [No Abstract] [Full Text] [Related]
8. Application of Bioactive Compounds and Drugs to Target Epigenetic Enzymes and Non-coding RNAs, Exploiting New Delivery Systems for Cancer Therapy. Poltronieri P; Mallardo M; Farooqi AA Anticancer Agents Med Chem; 2021; 21(5):544-545. PubMed ID: 33653237 [No Abstract] [Full Text] [Related]
9. Zebularine: a candidate for epigenetic cancer therapy. Bradbury J Drug Discov Today; 2004 Nov; 9(21):906-7. PubMed ID: 15501719 [TBL] [Abstract][Full Text] [Related]
10. Editorial overview: Cancer: Changing the landscape - new pharmacology steering the course towards improved treatment options in cancer. Phipps AN Curr Opin Pharmacol; 2015 Aug; 23():iv-vi. PubMed ID: 26091611 [No Abstract] [Full Text] [Related]
12. Chemical inhibitors make their RNA epigenetic mark. Cully M Nat Rev Drug Discov; 2019 Nov; 18(12):892-894. PubMed ID: 31780844 [No Abstract] [Full Text] [Related]
13. Epigenetic perspectives on cancer chemotherapy response. Liu MZ; McLeod HL; He FZ; Chen XP; Zhou HH; Shu Y; Zhang W Pharmacogenomics; 2014 Apr; 15(5):699-715. PubMed ID: 24798726 [TBL] [Abstract][Full Text] [Related]
14. The failure of epigenetic combination therapy for cancer and what it might be telling us about DNA methylation inhibitors. Yang AS; Yang BJ Epigenomics; 2016 Jan; 8(1):9-12. PubMed ID: 26698294 [No Abstract] [Full Text] [Related]
15. Epigenetic therapies reach main street. Bates SE Clin Cancer Res; 2009 Jun; 15(12):3917. PubMed ID: 19528089 [No Abstract] [Full Text] [Related]
16. Epigenetic drugs take on cancer. Kaiser J Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620 [No Abstract] [Full Text] [Related]
18. Epigenetic opportunities and challenges in cancer. Best JD; Carey N Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050 [TBL] [Abstract][Full Text] [Related]
19. Epigenetics meets immune checkpoints. Covre A; Coral S; Di Giacomo AM; Taverna P; Azab M; Maio M Semin Oncol; 2015 Jun; 42(3):506-13. PubMed ID: 25965370 [TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer. Hede K J Natl Cancer Inst; 2006 Mar; 98(6):377-9. PubMed ID: 16537828 [No Abstract] [Full Text] [Related] [Next] [New Search]